Eannatto Gamma-Tocotrienol and Hydroxy-Chavicol Synergistically Inhibits Growth and Induces Apoptosis of Human Glioma Cells

Investigating the interaction of Gamma-Tocotrienol (GTT) and Hydroxy-chavicol (HC) and its mode of cell death on glioma cell lines.
The following abstract is taken from a published study and is explained in simple terms to help you understand better. For deeper and technical insights regarding the action of Tocotrienols on human glioma cells, kindly refer to the reference link provided at the bottom of this abstract.
TOCOTRIENOLS CAN SUPPORT

APOPTOSIS IN GLIOMA CANCER CELLS

ANTI-CELL PROLIFERATION

TUMOR-GROWTH SUPPRESSION

ANTI-ANGIOGENESIS
Introduction to Glioblastoma, Brain Cancer, and Gamma-Tocotrienol
Glioblastoma or brain cancer is the 10th leading cause of death for both men and women. Glioblastomas are tumors that are formed of a large portion of tumor cells that keep dividing and reproducing at an alarming rate because they are well-nourished by the abnormal tumor blood supply.
Glioblastomas are very infiltrative and invasive as they invade into other regions of the brain and cause problems. Hence it is very necessary that it should be treated with the help of an agent that can suppress tumor growth and prevent the formation of blood vessels in the tumor (anti-angiogenesis). In this study, the interaction of Gamma-Tocotrienol (GCC) and Hydroxy-chavicol (HC) and its mode of cell death on glioma cell lines was observed.
How does Gamma-Tocotrienol fight Glioblastoma or Brain Cancer?
In the study, it was observed that the sub-lethal doses of the combination of Gamma-Tocotrienol (GTT) and Hydroxy-chavicol (HC), greatly suppressed the cell proliferation of glioma cancer cells and exhibited strong synergistic effects. Gamma-Tocotrienol has been observed to exhibit properties like angiogenesis, anti-call proliferation, apoptosis, and anti-inflammation. In this study too, it was observed that GTT along with HC, was able to exert synergistic inhibition of cell proliferation through induction of apoptosis in human glioma cancer cells in vitro.
Suggested Usage:
Eannatto DeltaGold Tocotrienol contains 90% Delta-Tocotrienol and 10% Gamma-Tocotrienol. One bottle of Eannatto Tocotrienols contains 125g, 60 gels. In studies, 400-900g of dosage of Tocotrienols, have been suggested by researchers for patients suffering from cancer. Eannatto Tocotrienol has been derived from the Annatto plant, found in the Amazon which is 100% Tocopherol free. Also, Annatto contains 2x more Tocotrienols than Palm oil and 3x more Tocotrienols than rice bran oil.
Reference for the Study in detail:
1. https://pubmed.ncbi.nlm.nih.gov/24980711/
2. https://www.cancer.net/cancer-types/brain-tumor/statistics
3. https://www.abta.org/tumor_types/glioblastoma-gbm/
4. XIAP as a Target of New Small Organic Natural Molecules Inducing Human Cancer Cell Death. Muñoz D, et al. Cancers (Basel). 2019. PMID: 31505859
5. Transcriptome analysis reveals the molecular mechanisms of combined gamma-tocotrienol and hydroxychavicol in preventing the proliferation of 1321N1, SW1783, and LN18 glioma cancer cells. Abdul Rahman A, et al. J Physiol Biochem. 2019. PMID: 31414341
6. γ-Tocotrienol Inhibits Proliferation and Induces Apoptosis Via the Mitochondrial Pathway in Human Cervical Cancer HeLa Cells. Xu W, et al. Molecules. 2017. PMID: 28777347
7.Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Gene Dev. 2007;21(21):2683–2710. DOI: 10.1101/gad.1596707. – DOI – PubMed
8. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol. 2006;8(1):12–26. DOI: 10.1215/S1522851705000268. – DOIPMCPubMed
9. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med. 2007;131(3):397–406. – PubMed
10. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. DOI: 10.1016/S1470-2045(09)70025-7. – DOI – PubMed
11.Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2–3):97–110.
Add to cart